HC Wainwright Issues Optimistic Outlook for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Equities researchers at HC Wainwright raised their Q2 2026 earnings estimates for shares of Greenwich LifeSciences in a research report issued on Tuesday, July 21st. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.30) for the quarter, up from their previous estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $69.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ FY2026 earnings at ($1.29) EPS and FY2027 earnings at ($1.17) EPS.

Several other research firms have also recently weighed in on GLSI. Wall Street Zen cut Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $57.00.

Greenwich LifeSciences Price Performance

GLSI stock opened at $13.19 on Thursday. Greenwich LifeSciences has a 1 year low of $7.78 and a 1 year high of $34.10. The company has a market cap of $193.63 million, a P/E ratio of -8.40 and a beta of 1.40. The firm has a 50-day moving average of $22.43 and a 200 day moving average of $24.45.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after acquiring an additional 13,179 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Greenwich LifeSciences by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after purchasing an additional 9,568 shares during the last quarter. State Street Corp lifted its holdings in shares of Greenwich LifeSciences by 19.3% during the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after purchasing an additional 15,831 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $509,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Greenwich LifeSciences by 235.5% in the 1st quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after purchasing an additional 32,657 shares in the last quarter. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences News Roundup

Here are the key news stories impacting Greenwich LifeSciences this week:

• Positive Sentiment: UK regulators approved expansion of the company’s Phase III FLAMINGO-01 breast cancer trial into the United Kingdom, potentially adding 5-10 new sites and broadening patient enrollment. Greenwich LifeSciences said the move was supported by patient interest and its collaboration with The Royal Marsden, which could improve visibility and trial momentum for GLSI-100. Article Title
• Positive Sentiment: HC Wainwright maintained a Buy rating and $69 price target on GLSI while slightly lifting its Q2 2026 EPS estimate and reiterating longer-term forecasts. Even though the company is still expected to post losses, the higher estimates and bullish rating suggest analysts remain constructive on the stock’s clinical upside. Article Title
• Neutral Sentiment: HC Wainwright also set out FY2026 and FY2027 EPS estimates, both still negative, indicating Greenwich LifeSciences remains a pre-revenue clinical-stage biotech with ongoing losses. That keeps valuation tied heavily to trial progress rather than near-term earnings. Article Title
• Neutral Sentiment: Investor materials highlighted preliminary FLAMINGO-01 data showing a roughly 70-80% reduction in recurrence rates in one arm of the study, but the company emphasized the results are not final and remain subject to clinical uncertainty. The data are encouraging, but still early enough that investors are likely to wait for more definitive readouts. Article Title

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.